RNIB requires wet AMD patients for research

Article

The Royal National Institute of the Blind (RNIB) require 300 patients and carers to participate in two research projects.

The Royal National Institute of the Blind (RNIB) require 300 patients and carers to participate in two research projects.

They need 100 wet AMD patients, 100 carers of people with wet AMD and 100 patients with cataract. The aim of the research is to assess the impact of restrictions on treatment access and to ask eye health specialists how their services are delivered.

Patients must have been diagnosed and treated for either wet AMD or cataracts in the last three years. This can include those who are still undergoing treatment or have completed it.

Research will be conducted confidentially over the telephone and reports will be published in Spring 2013. The results will enable the RNIB to campaign for primary care trusts to alter their policies and improve treatment access.

To enter patients who are interested in taking part please email campaigns@rnib.org.uk by Friday 14th December 2012.

For further information visit the website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.